Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
11 Janeiro 2022 - 8:30AM
Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating
in the field of oral biotherapeutics for gastrointestinal health
and beyond, today announced that patient data on indicators of
efficacy in the treatment of gastrointestinal disorders has been
accepted for oral presentation during the 34th edition of the
Belgian Week of Gastroenterology, February 9-11, 2022.
Details of the presentations are as follows:
|
Presentation Title: |
Endoscopic outcome in tofacitinib treated patients correlated with
tofacitinib tissue exposure |
|
Presenter Name: |
Bram Verstockt, MD, PhD |
|
Session Date & Time: |
February 9, 2022, 9:24 to 9:34
CET |
The abstract is now available on the BWGE 2022 website.
About Progenity
Progenity, Inc. is a biotechnology company innovating in the
fields of women’s health, gastrointestinal health and oral
biotherapeutics. Progenity applies a multi-omics approach,
combining genomics, epigenomics, proteomics, and metabolomics to
its molecular testing products and to the development of a suite of
investigational ingestible devices designed to provide precise
diagnostic sampling and drug delivery solutions. Progenity’s vision
is to transform healthcare to become more precise and personal by
improving diagnoses of disease and improving patient outcomes
through localized treatment with targeted therapies.
For more information visit www.progenity.com, or follow the
company on LinkedIn or Twitter.
Investor Contact:Robert UhlManaging Director,
ICR Westwickeir@progenity.com (619) 228-5886
Media Contact:Kristin SchaefferCG
Lifemedia@progenity.com 858-457-2436
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:PROG)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Biora Therapeutics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de